Phytochemicals with epigenetic properties and their role in melanoma therapy.
1/5 보강
Malignant melanoma is the most aggressive and lethal type of skin cancer associated with increased mortality rates.
APA
Anestopoulos I, Kyriakou S, et al. (2026). Phytochemicals with epigenetic properties and their role in melanoma therapy.. International review of cell and molecular biology, 400, 1-30. https://doi.org/10.1016/bs.ircmb.2024.12.001
MLA
Anestopoulos I, et al.. "Phytochemicals with epigenetic properties and their role in melanoma therapy.." International review of cell and molecular biology, vol. 400, 2026, pp. 1-30.
PMID
41905784 ↗
Abstract 한글 요약
Malignant melanoma is the most aggressive and lethal type of skin cancer associated with increased mortality rates. Moreover, beyond the genetic background, the altered epigenetic landscape (e.g., abnormal patterns of DNA methylation, aberrant histone modifications and de-regulated expression levels of ncRNAs) further contributes to the pathophysiology of the disease. In addition, despite the improvement of current anti-melanoma strategies and the development of new therapeutic approaches, the 5-year survival among melanoma patients is still high, mainly due to acquired-drug resistance. On the other hand, phytochemicals have been associated with various health-promoting properties through pleiotropic mechanisms including acting as potent epigenetic regulators restoring back a normal phenotype in various experimental cancer models. In this review article, we discuss the general characteristics of malignant melanoma and current therapeutic approaches while we report the epigenetic basis of the disease along with the main compounds capable of restoring a normal epigenetic landscape. Finally, we describe the role of various phytochemicals in targeting the epigenome of malignant melanoma thereby potentially acting as an alternative therapeutic approach.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.